Found 5 articles for: "Onychomycosis"
Number of Affected Nails Is the Primary Determinant of Efinaconazole 10% Solution Usage for Onychomycosis
February 2024 | Volume 23 | Issue 2 | Editorials | 110 | Copyright © February 2024
Good adherence to treatment is necessary for the successful treatment of onychomycosis and requires that an appropriate amount of medication be prescribed. Most prescriptions for efinaconazole 10...
Read MoreOnychomycosis Treatment Prescribed at Only Twenty Percent of Visits: A Cross-Sectional Analysis of the National Ambulatory Medical Care Survey 2007 to 2016
October 2023 | Volume 22 | Issue 10 | Original Article | 1040 | Copyright © October 2023
Background: Onychomycosis represents the highest proportion of nail disorders seen in clinical practice. Onychomycosis management may differ amongst specialties, with impact on patien...
Read MoreComparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis
October 2023 | Volume 22 | Issue 10 | Original Article | 1017 | Copyright © October 2023
Recently, treatment outcomes in patients with toenail onychomycosis have improved considerably due to more effective oral antifungal medications such as terbinafine and itraconazole. These medica...
Read MoreCurrent Issues in Global Onychomycosis Management
April 2022 | Volume 21 | Issue 4 | Original Article | 371 | Copyright © April 2022
Introduction: Onychomycoses occur worldwide and are complex infections to treat. Diagnosis with standard culture methods has been problematic. Treatment historically used oral monothe...
Read MoreTherapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US
October 2021 | Volume 20 | Issue 10 | Original Article | 1076 | Copyright © October 2021
Background: Onychomycosis affects around 14% of individuals in North America and Europe and is undertreated. Treatment is challenging as toenail growth can take 12–18 months, th...
Read More
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.